Wells Fargo & Company Poseida Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 27,833 shares of PSTX stock, worth $75,427. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,833
Previous 24,030
15.83%
Holding current value
$75,427
Previous $76,000
6.58%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PSTX
# of Institutions
95Shares Held
38.1MCall Options Held
417KPut Options Held
42.7K-
Pentwater Capital Management LP Naples, FL5.98MShares$16.2 Million0.23% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$13.3 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.48MShares$12.1 Million0.73% of portfolio
-
Silverarc Capital Management, LLC3.61MShares$9.78 Million2.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$9.23 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $232M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...